IL2 and neoplasm: Additionally, conducting trials to explore the synergistic effects of NK cell therapy with cytokines (e.g., IL-2, IL-15) or other immune stimulants to boost NK cell activity and sustain anti-tumor responses will provide beneficial outcomes.